Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Informe acción SEHK:1349

Capitalización de mercado: HK$6.9b

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Da Jun Zhao

Chief Executive Officer (CEO)

CN¥2.2m

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO22.3yrs
Participación del CEO1.5%
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directiva4yrs

Actualizaciones recientes de la dirección

Recent updates

Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders

May 06
Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders

What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

Apr 12
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Mar 22
We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Mar 07
Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Feb 20
Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Feb 07
Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Jan 25
Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Jan 12
Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Dec 28
Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Dec 15
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Dec 03
Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 21
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Da Jun Zhao en comparación con los beneficios de Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

CN¥102m

Dec 31 2023n/an/a

CN¥109m

Sep 30 2023n/an/a

CN¥191m

Jun 30 2023n/an/a

CN¥242m

Mar 31 2023n/an/a

CN¥142m

Dec 31 2022CN¥2mn/a

CN¥138m

Sep 30 2022n/an/a

CN¥132m

Jun 30 2022n/an/a

CN¥112m

Mar 31 2022n/an/a

CN¥213m

Dec 31 2021CN¥5mCN¥2m

CN¥213m

Sep 30 2021n/an/a

CN¥198m

Jun 30 2021n/an/a

CN¥201m

Mar 31 2021n/an/a

CN¥188m

Dec 31 2020CN¥3mCN¥1m

CN¥165m

Sep 30 2020n/an/a

CN¥191m

Jun 30 2020n/an/a

CN¥165m

Mar 31 2020n/an/a

CN¥204m

Dec 31 2019CN¥3mCN¥1m

CN¥227m

Sep 30 2019n/an/a

CN¥151m

Jun 30 2019n/an/a

CN¥151m

Mar 31 2019n/an/a

CN¥91m

Dec 31 2018CN¥2mCN¥1m

CN¥112m

Sep 30 2018n/an/a

CN¥95m

Jun 30 2018n/an/a

CN¥78m

Mar 31 2018n/an/a

CN¥77m

Dec 31 2017CN¥1mCN¥1m

CN¥75m

Compensación vs. Mercado: La compensación total de Da Jun($USD306.94K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD520.90K).

Compensación vs. Ingresos: La compensación de Da Jun ha sido consistente con los resultados de la empresa en el último año.


CEO

Da Jun Zhao (53 yo)

22.3yrs

Permanencia

CN¥2,224,000

Compensación

Mr. Da Jun Zhao has been an Executive Director at Taizhou SPH Pharmaceutical Co., Ltd. since January 2002. Mr. Zhao Co-Founded Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.in November 1996 and ser...


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Da Jun Zhao
Co-Founder22.3yrsCN¥2.22m1.51%
CN¥ 103.4m
Xue Yan
CFO, Deputy GMless than a yearCN¥2.02m0.20%
CN¥ 13.8m
Xiao Yang Yu
Non-Executive Director11yrssin datossin datos
Ai Guo Zhou
Member of Supervisory Committeeno datasin datossin datos
Bo Shen
Non Executive Director11.9yrssin datossin datos
Jian Huang
Independent Chairman of Supervisory Committee6.9yrssin datossin datos
Hong Guang Wang
Independent Non-Executive Directorless than a yearsin datossin datos
Siu Wing Lam
Independent Non-Executive Directorless than a yearsin datossin datos
Pei Long Xu
Independent Non-Executive Directorless than a yearsin datossin datos
Ya Nan Qu
Member of Supervisory Committeeno datasin datos0.0038%
CN¥ 258.0k

4.0yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de 1349 se considera experimentada (3.9 años de antigüedad promedio).